BRIEF—EC approves new easy-to-use, once-weekly Bydureon BCise pen for patients with type-2 diabetes

AstraZeneca today announced that the European Commission (EC) has approved Bydureon BCise(exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorization for Bydureon (exenatide extended release) for the treatment of patients with type-2 diabetes.

The new formulation of once-weekly Bydureonis an improved single-dose, pre-filled pen device that requires no titration and is approved for use in combination with other glucose-lowering medicines, including basal insulin, to help improve glycemic control in adults with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise, says the Anglo-Swedish drug major.